Mercaptopurine oral suspension

Drug Profile

Mercaptopurine oral suspension

Alternative Names: Allmercap; Purixan; Xaluprine

Latest Information Update: 24 Sep 2015

Price : $50

At a glance

  • Originator Nova Laboratories
  • Class Antineoplastics; Purines; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia

Most Recent Events

  • 08 Apr 2015 The product is approved for Acute lymphoblastic leukaemia in European Union
  • 18 Feb 2015 Launched for Acute lymphoblastic leukaemia in USA and Czech Republic (PO) prior to February 2015
  • 17 Jun 2014 Mercaptopurine oral suspension licensed to LINK Healthcare in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top